Vitamin D supplementation does not hamper kidney function in adults with prediabetes

Written By :  Dr. Nandita Mohan
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-08-12 03:30 GMT   |   Update On 2021-08-12 03:30 GMT

Among persons with prediabetes, who were not preselected on the basis of serum 25(OH)D concentration, vitamin D supplementation did not affect progression kidney disease scores and did not have a meaningful effect on change in urine albumin-to-creatinine ratio, suggests a recent study published in the Clinical Journal of American Society of Nephrology. Low serum...

Login or Register to read the full article

Among persons with prediabetes, who were not preselected on the basis of serum 25(OH)D concentration, vitamin D supplementation did not affect progression kidney disease scores and did not have a meaningful effect on change in urine albumin-to-creatinine ratio, suggests a recent study published in the Clinical Journal of American Society of Nephrology.

Low serum 25-hydroxyvitamin D (25[OH]D) concentration has been associated with higher levels of proteinuria and lower levels of eGFR in observational studies.

Sun H. Kim and colleagues from the Division of Endocrinology, Gerontology and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, California investigated the effect of vitamin D supplementation on kidney outcomes in a population with prediabetes.

Overweight/obese adults with high risk for type 2 diabetes were randomized to vitamin D3 4000 IU per day versus placebo. Median duration of treatment was 2.9 years (interquartile range 2.0–3.5 years).

Kidney outcomes included (1) worsening in Kidney Disease: Improving Global Outcomes (KDIGO ) risk score (low, moderate, high, very high) on two consecutive follow-up visits after the baseline visit and (2) mean changes in eGFR and urine albumin-to-creatinine ratio (UACR).

The following findings were observed-

a. Among 2166 participants (mean age 60 years, body mass index 32 kg/m2, serum 25(OH)D 28 ng/ml, eGFR 87 ml/min per 1.73 m2, UACR 11 mg/g, 79% with hypertension), 10% had moderate, high, or very high KDIGO risk score.

b. Over a median follow-up of 2.9 years, there were 28 cases of KDIGO worsening in the vitamin D group and 30 in the placebo group (hazard ratio, 0.89; 95% confidence interval [95% CI], 0.52 to 1.52]).

c. Mean difference in eGFR from baseline was −1.0 ml/min per 1.73 m2 (95% CI, −1.3 to −0.7) in the vitamin D group and −0.1 ml/min per 1.73 m2 (95% CI, −0.4 to 0.2) in the placebo group; between-group difference was −1.0 ml/min per 1.73 m2 (95% CI, −1.4 to −0.6).

d. Mean difference in UACR was 2.7 mg/g (95% CI, 1.2 to 4.3) in the vitamin D group and 2.0 (95% CI, 0.5 to 3.6) in the placebo group; between-group difference was 0.7 mg/g (95% CI, −1.5 to 2.9).

As a result, the authors concluded that among persons with prediabetes, who were not preselected on the basis of serum 25(OH)D concentration, vitamin D supplementation did not affect progression of KDIGO risk scores and did not have a meaningful effect on change in urine albumin-to-creatinine ratio.

https://doi.org/10.2215/CJN.00420121


Tags:    
Article Source : Clinical Journal of American Society of Nephrology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News